Galectin Therapeutics Stock Price, News & Analysis (NASDAQ:GALT)

$2.35 -0.04 (-1.67 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.35
Today's Range$2.20 - $2.43
52-Week Range$0.88 - $3.68
Volume478,760 shs
Average Volume1.28 million shs
Market Capitalization$85.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56

About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Debt-to-Equity RatioN/A
Current Ratio1.62%
Quick Ratio1.62%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book23.50

Profitability

Trailing EPS($0.55)
Net Income$-21,430,000.00
Net MarginsN/A
Return on Equity-1,747.01%
Return on Assets-160.00%

Miscellaneous

Employees7
Outstanding Shares35,640,000

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Tuesday, November, 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. View Galectin Therapeutics' Earnings History.

When will Galectin Therapeutics make its next earnings announcement?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for Galectin Therapeutics.

Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2017?

4 equities research analysts have issued twelve-month price targets for Galectin Therapeutics' stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate Galectin Therapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Galectin Therapeutics.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:

  • Marc Rubin M.D., Chairman of the Board (Age 62)
  • Peter G. Traber M.D., President, Chief Executive Officer, Chief Medical Officer, Director (Age 61)
  • Jack W. Callicutt, Chief Financial Officer (Age 48)
  • Harold H. Shlevin M.D., Ph.D., Chief Operating Officer, Secretary (Age 66)
  • Eliezer Zomer Ph.D., Executive Vice President - Manufacturing and Product Development (Age 68)
  • J. Rex Horton, Executive Director - Regulatory Affairs and Quality Assurance (Age 45)
  • James C. Czirr, Director (Age 62)
  • Gilbert F. Amelio Ph.D., Independent Director (Age 73)
  • Kevin D. Freeman, Independent Director (Age 54)
  • Arthur R. Greenberg, Independent Director (Age 68)

Who owns Galectin Therapeutics stock?

Galectin Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include D.A. Davidson & CO. (1.74%) and Advisor Group Inc. (1.31%). Company insiders that own Galectin Therapeutics stock include Arthur Greenberg, James C Czirr, Marc Rubin and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

Who sold Galectin Therapeutics stock? Who is selling Galectin Therapeutics stock?

Galectin Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO.. View Insider Buying and Selling for Galectin Therapeutics.

Who bought Galectin Therapeutics stock? Who is buying Galectin Therapeutics stock?

Galectin Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Inc.. Company insiders that have bought Galectin Therapeutics stock in the last two years include Arthur Greenberg, Marc Rubin and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics.

How do I buy Galectin Therapeutics stock?

Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of Galectin Therapeutics stock can currently be purchased for approximately $2.35.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $85.18 million. The company earns $-21,430,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Galectin Therapeutics employs 7 workers across the globe.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (GALT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galectin Therapeutics (NASDAQ:GALT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.752.752.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$4.63$2.08$2.08
Price Target Upside: 224.68% upside84.26% upside6.16% downside6.16% downside

Galectin Therapeutics (NASDAQ:GALT) Consensus Price Target History

Price Target History for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2017Roth CapitalLower Price TargetBuy$10.00 -> $3.00HighView Rating Details
12/7/2017HC WainwrightReiterated RatingBuy$6.00 -> $10.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Galectin Therapeutics (NASDAQ:GALT) Earnings History and Estimates Chart

Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ GALT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2018        
11/7/2017Q3 2017($0.15)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Galectin Therapeutics (NASDAQ:GALT) Earnings Estimates

2017 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.15)($0.13)($0.14)
Q2 20172($0.16)($0.10)($0.13)
Q3 20172($0.12)($0.10)($0.11)
Q4 20173($0.12)($0.09)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Galectin Therapeutics (NASDAQ GALT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 38.80%
Institutional Ownership Percentage: 11.07%
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ GALT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Marc RubinDirectorBuy7,000$1.85$12,950.00View SEC Filing  
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.00View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Galectin Therapeutics (NASDAQ GALT) News Headlines

Source:
DateHeadline
 Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.11 Earnings Per Share Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - December 14 at 1:30 PM
Galectin Therapeutics (GALT) Provides Corporate Update - StreetInsider.comGalectin Therapeutics (GALT) Provides Corporate Update - StreetInsider.com
www.streetinsider.com - December 14 at 9:43 AM
Galectin Therapeutics Provides Corporate Update at Annual MeetingGalectin Therapeutics Provides Corporate Update at Annual Meeting
finance.yahoo.com - December 14 at 9:43 AM
Regulus Therapeutics (RGLS) and Galectin Therapeutics (GALT) Head-To-Head ReviewRegulus Therapeutics (RGLS) and Galectin Therapeutics (GALT) Head-To-Head Review
www.americanbankingnews.com - December 10 at 11:34 PM
Galectin Therapeutics (GALT) Downgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 8 at 8:30 PM
Galectin Therapeutics Inc. (GALT) Director Buys $12,950.00 in StockGalectin Therapeutics Inc. (GALT) Director Buys $12,950.00 in Stock
www.americanbankingnews.com - December 8 at 6:48 PM
Galectin Therapeutics Inc. (GALT) to Post FY2018 Earnings of ($0.50) Per Share, Seaport Global Securities ForecastsGalectin Therapeutics Inc. (GALT) to Post FY2018 Earnings of ($0.50) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - December 8 at 12:36 PM
Galectin Therapeutics Inc. (GALT) Receives Average Recommendation of "Buy" from AnalystsGalectin Therapeutics Inc. (GALT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 8 at 11:42 AM
Galectin Therapeutics: Time To Exit - Seeking AlphaGalectin Therapeutics: Time To Exit - Seeking Alpha
seekingalpha.com - December 8 at 9:36 AM
Galectin Therapeutics (GALT) Given New $3.00 Price Target at Roth CapitalGalectin Therapeutics (GALT) Given New $3.00 Price Target at Roth Capital
www.americanbankingnews.com - December 7 at 5:00 PM
Galectin Therapeutics (GALT) Receives "Buy" Rating from HC WainwrightGalectin Therapeutics (GALT) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - December 7 at 8:02 AM
Today’s Research Reports on Stocks to Watch: Allergan plc and Galectin TherapeuticsToday’s Research Reports on Stocks to Watch: Allergan plc and Galectin Therapeutics
finance.yahoo.com - December 6 at 9:46 AM
Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial FailureGalectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure
finance.yahoo.com - December 5 at 5:12 PM
Galectin Therapeutics (GALT) Phase 2b NASH-CX Trial Did Not Reach Primary EndpointGalectin Therapeutics (GALT) Phase 2b NASH-CX Trial Did Not Reach Primary Endpoint
www.streetinsider.com - December 5 at 10:16 AM
Galectin says NASH drug misses main goal of midstage trialGalectin says NASH drug misses main goal of midstage trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics stock drops nearly 50% after negative trial resultsGalectin Therapeutics stock drops nearly 50% after negative trial results
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics Announces Results from Phase 2b NASH-CX TrialGalectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin slumps after NASH drug misses main goal of mid-stage trialGalectin slumps after NASH drug misses main goal of mid-stage trial
finance.yahoo.com - December 5 at 10:16 AM
Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
finance.yahoo.com - December 4 at 5:14 PM
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options - NasdaqImplied Volatility Surging for Galectin Therapeutics (GALT) Stock Options - Nasdaq
www.nasdaq.com - December 3 at 5:15 PM
Galectin Therapeutics (GALT) Downgraded by ValuEngineGalectin Therapeutics (GALT) Downgraded by ValuEngine
www.americanbankingnews.com - December 3 at 12:44 PM
Implied Volatility Surging for Galectin Therapeutics (GALT) Stock OptionsImplied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
finance.yahoo.com - December 1 at 4:56 PM
Galectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment ResearchGalectin Therapeutics (GALT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 30 at 11:02 PM
Analyzing Galectin Therapeutics (GALT) & Its RivalsAnalyzing Galectin Therapeutics (GALT) & Its Rivals
www.americanbankingnews.com - November 29 at 3:20 PM
HC Wainwright Raises Galectin Therapeutics (GALT) Price Target to $6.00HC Wainwright Raises Galectin Therapeutics (GALT) Price Target to $6.00
www.americanbankingnews.com - November 28 at 7:12 PM
Galectin Therapeutics CEO Peter G. Traber, MD Named Chair of the Anti-Fibrotic Drug Development Summit 2017 - GlobeNewswire (press release)Galectin Therapeutics CEO Peter G. Traber, MD Named Chair of the Anti-Fibrotic Drug Development Summit 2017 - GlobeNewswire (press release)
globenewswire.com - November 14 at 12:12 AM
Galectin Therapeutics (GALT) Says Combination Immunotherapy of Pembrolizumab with its Inhibitor GR-MD-02 Shows ... - StreetInsider.comGalectin Therapeutics (GALT) Says Combination Immunotherapy of Pembrolizumab with its Inhibitor GR-MD-02 Shows ... - StreetInsider.com
www.streetinsider.com - November 14 at 12:12 AM
Galectin Therapeutics Inc. (GALT) Given Average Recommendation of "Hold" by BrokeragesGalectin Therapeutics Inc. (GALT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 13 at 12:34 PM
The objective response rate in advanced melanoma was 62.5% (five of eight subjects)The objective response rate in advanced melanoma was 62.5% (five of eight subjects)
www.nasdaq.com - November 13 at 9:49 AM
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
finance.yahoo.com - November 13 at 9:48 AM
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
finance.yahoo.com - November 13 at 9:48 AM
Seaport Global Securities Weighs in on Galectin Therapeutics Inc.s Q4 2017 Earnings (GALT)Seaport Global Securities Weighs in on Galectin Therapeutics Inc.'s Q4 2017 Earnings (GALT)
www.americanbankingnews.com - November 10 at 8:56 AM
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
finance.yahoo.com - November 8 at 7:46 AM
Galectin Therapeutics Inc. (GALT) Posts  Earnings Results, Beats Expectations By $0.02 EPSGalectin Therapeutics Inc. (GALT) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 7 at 11:32 AM
Galectin Therapeutics Inc. (GALT) Set to Announce Earnings on MondayGalectin Therapeutics Inc. (GALT) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 9:37 AM
Galectin Therapeutics (GALT) to Present Clinical Data Showing Ability of Non-Invasive Test to Identify Clinically ... - StreetInsider.comGalectin Therapeutics (GALT) to Present Clinical Data Showing Ability of Non-Invasive Test to Identify Clinically ... - StreetInsider.com
www.streetinsider.com - October 21 at 11:06 PM
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
feeds.benzinga.com - October 20 at 8:53 AM
Roth Capital Starts Galectin Therapeutics (GALT) at Buy - StreetInsider.comRoth Capital Starts Galectin Therapeutics (GALT) at Buy - StreetInsider.com
www.streetinsider.com - October 19 at 7:39 PM
Galectin Therapeutics Inc. (GALT) Receives Consensus Recommendation of "Hold" from AnalystsGalectin Therapeutics Inc. (GALT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 19 at 1:24 PM
Roth Capital Initiates Coverage on Galectin Therapeutics Inc. (GALT)Roth Capital Initiates Coverage on Galectin Therapeutics Inc. (GALT)
www.americanbankingnews.com - October 19 at 11:44 AM
Zacks: Brokerages Expect Galectin Therapeutics Inc. (GALT) to Announce -$0.14 Earnings Per ShareZacks: Brokerages Expect Galectin Therapeutics Inc. (GALT) to Announce -$0.14 Earnings Per Share
www.americanbankingnews.com - October 19 at 2:08 AM
Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher - NasdaqGalectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher - Nasdaq
www.nasdaq.com - October 12 at 1:49 AM
Organovo Holdings (ONVO) and Galectin Therapeutics (GALT) Financial ContrastOrganovo Holdings (ONVO) and Galectin Therapeutics (GALT) Financial Contrast
www.americanbankingnews.com - October 11 at 8:38 AM
Galectin Therapeutics Inc. (GALT) Receives New Coverage from Analysts at Seaport Global SecuritiesGalectin Therapeutics Inc. (GALT) Receives New Coverage from Analysts at Seaport Global Securities
www.americanbankingnews.com - October 7 at 3:36 PM
NASH Contender Galectin Therapeutics Could Run Up Nicely - But Dont Stick Around - Seeking AlphaNASH Contender Galectin Therapeutics Could Run Up Nicely - But Don't Stick Around - Seeking Alpha
seekingalpha.com - October 4 at 5:49 PM
Kidney Function Tests - Global Market Outlook (2017-2023)Kidney Function Tests - Global Market Outlook (2017-2023)
www.prnewswire.com - October 4 at 10:56 AM
Intercept Runs Into Trouble; Other NASH Developers, Like Galectin, Gain Value - Seeking AlphaIntercept Runs Into Trouble; Other NASH Developers, Like Galectin, Gain Value - Seeking Alpha
seekingalpha.com - September 29 at 7:30 PM
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
finance.yahoo.com - September 25 at 10:58 AM
Galectin Therapeutics (GALT) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowGalectin Therapeutics (GALT) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:01 AM
Galectin Therapeutics (GALT) Receives Chinese Patent for Composition of Matter for GR-MD-02 - StreetInsider.comGalectin Therapeutics (GALT) Receives Chinese Patent for Composition of Matter for GR-MD-02 - StreetInsider.com
www.streetinsider.com - September 12 at 7:44 PM

SEC Filings

Galectin Therapeutics (NASDAQ:GALT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galectin Therapeutics (NASDAQ:GALT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galectin Therapeutics (NASDAQ GALT) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.